ICU Medical, Inc. (ICUI) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps.
Is ICU Medical, Inc. stock overvalued or undervalued in 2026?
ICU Medical, Inc. (ICUI) trades at 141× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $36 (-78 %).
Kaplio overview: ICU Medical, Inc.
Market cap $4B · 52 weeks $115 – $187 (11 % below the high) · P/E 141× · 2027 expected P/E 17.2× · Dividend none · Next earnings November 5, 2026 · expected EPS $2.14 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/E 141.0× (expensive).
- Business: ROIC −22 % (weak).
- Balance sheet: Net debt/EBITDA 3.3× (fragile).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $36 (-78 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 3.9 %, fails.
- 5y EPS growth −62.8 %, fails.
- Gross margin 36.8 %, fails.
- ROIC −21.7 %, fails.
- Net debt / EBITDA 3.3×, fails.
- FCF / Net Income 12,541.5 %, passes.
- P/E vs own 10y history 141.0×, passes.
Against its peers (reference peers) — ICU Medical, Inc.: P/E 141×; EV/EBITDA 20.4×; ROIC -21.7 %; $4.2B. Baxter International Inc. (P/E —; EV/EBITDA 27.6×; ROIC -1.6 %; $13.2B), Becton, Dickinson and Company (P/E 58.8×; EV/EBITDA 15.5×; ROIC 3.7 %; $53.2B), Envista Holdings Corp (P/E 41.3×; EV/EBITDA 10.4×; ROIC 2.4 %; $3.8B).
Expensive or cheap against its last 6 years?
P/E at each close: today 141× · median 47.9× · minimum 28.1× · maximum 141× · cheap below 40.7× · expensive above 60.5×. It has been cheaper than today 100% of the time over its last 6 years.
Profitability
| Return on Equity | 1.41% |
| Return on Invested Capital | -21.74% |
| Return on Assets | 0.76% |
| Gross Margin | 37.56% |
| Operating Margin | 5.04% |
| Net Margin | 1.39% |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 2.43 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 2.17 |
Price Performance
| 1 month | +1.80% |
| 3 months | -1.26% |
| Year-to-date | +16.63% |
| 1 year | +41.40% |
| 3 years | +69.04% |
| 5 years | -28.93% |
| 10 years | +19.45% |
Related companies: BDX · BAX · TFX · ISRG · 0R29.L · 0R19.L · RMD · 0KW4.L
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of ICUI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks